| Literature DB >> 33273559 |
Seung-Hwa Lee1, Jungchan Park2, Jong-Hwan Lee3, Jeong Jin Min2, Kwan Young Hong2, Hyojin Cho2, Keumhee Carriere4,5, Joonghyun Ahn5.
Abstract
Although both pre- and postoperative myocardial injuries are strongly associated with an increased postoperative mortality, no study has directly compared the effects of pre- and postoperative myocardial injuries on 30-day mortality after non-cardiac surgery. Therefore, we evaluated and compared the effects of pre- and postoperative myocardial injury on 30-day mortality after non-cardiac surgery. From January 2010 to December 2016, patients undergoing non-cardiac surgery were stratified into either the normal (n = 3182), preoperative myocardial injury (n = 694), or postoperative myocardial injury (n = 756) groups according to the peak cardiac troponin value. Myocardial injury was defined as a sole elevation of cardiac troponin value above the 99th percentile upper reference limit without ischemic symptom using the 4th universal definition of myocardial infarction. Patients in the preoperative myocardial injury group were further divided into the attenuated (n = 177) or persistent myocardial injury group (n = 517) according to the normalization of cardiac troponin level in postoperative period. As the primary outcome, postoperative 30-day mortalities were compared among the groups using the weighted Cox proportional-hazards regression models with the inverse probability weighting. Compared with the normal group, postoperative 30-day mortality was increased significantly both in the pre- and postoperative myocardial injury groups (1.4% vs. 10.7%; hazard ratio [HR] 3.12; 95% confidence interval [CI] 1.62-6.01; p = 0.001 and 1.4% vs. 7.4%; HR 4.49; 95% CI 2.34-8.60; p < 0.001, respectively), however, there was no difference between the pre- and postoperative myocardial injury groups (HR, 1.44; 95% CI 0.79-2.64; p = 0.45). In addition, the attenuated myocardial injury group showed a significantly lower postoperative 30-day mortality than the persistent myocardial injury group (5.6% vs. 12.4%; HR 2.23; 95% CI 1.17-4.44; p = 0.02). In patients undergoing non-cardiac surgery, preoperative myocardial injury also increased postoperative 30-day mortality to a similar degree of postoperative myocardial injury. Further studies on the importance of preoperative myocardial injury are needed.Clinical trial number and registry URL: KCT0004348 ( www.cris.nih.go.kr ).Entities:
Year: 2020 PMID: 33273559 PMCID: PMC7713127 DOI: 10.1038/s41598-020-78023-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1The flowchart of the patients. Hs-cTnI, high sensitivity-cardiac troponin I.
Baseline characteristics of the study population.
| Entire population | Normal ( | Preoperative myocardial injury ( | Postoperative myocardial injury ( | SMD | IPW | |||
|---|---|---|---|---|---|---|---|---|
| SMD | ||||||||
| Male sex | 2852 (61.6) | 1957 (61.5) | 411 (59.2) | 484 (64) | 0.17 | 6.6 | 0.27 | 7.6 |
| Age, years | 65.6 (± 13.9) | 65.1 (± 12.8) | 66.7 (± 14.1) | 66.6 (± 13.2) | 8.1 | 0.08 | 6.4 | |
| BMI | 23.6 (± 3.83) | 23.9 (± 3.8) | 22.8 (± 3.9) | 23.3 (± 4.0) | 19.5 | 0.51 | 4 | |
| Hypertension | 2464 (53.2) | 1665 (52.4) | 368 (53.0) | 430 (56.9) | 0.08 | 6.1 | 0.62 | 4 |
| Diabetes | 1314 (28.4) | 836 (26.3) | 246 (35.4) | 232 (30.7) | < 0.001 | 13.3 | 0.76 | 2.5 |
| Current smoking | 572 (12.4) | 410 (12.9) | 76 (11.0) | 86 (11.4) | 0.25 | 4 | 0.94 | 1.2 |
| Previous myocardial infarction | 279 (6.0) | 156 (4.9) | 78 (11.2) | 45 (6.0) | < 0.001 | 0.78 | 2.3 | |
| Coronary revascularization | 714 (15.4) | 417 (13.1) | 144 (20.7) | 153 (20.2) | < 0.001 | 13.7 | 0.36 | 4.3 |
| Heart failure | 137 (3.0) | 53 (1.7) | 59 (8.5) | 25 (3.3) | < 0.001 | 21.4 | 0.06 | 7.7 |
| Arrhythmia | 486 (10.5) | 285 (9.0) | 112 (16.1) | 89 (11.8) | < 0.001 | 14.6 | 0.33 | 4.1 |
| Valve disease | 139 (3.0) | 77 (2.4) | 27 (3.9) | 35 (4.6) | 0.002 | 8 | 0.55 | 3.1 |
| Stroke | 666 (14.4) | 410 (12.9) | 127 (18.3) | 129 (17.1) | < 0.001 | 10 | 0.81 | 1.8 |
| Chronic kidney disease | 478 (10.3) | 185 (5.8) | 164 (23.6) | 129 (17.1) | < 0.001 | 34.7 | 0.34 | 4.7 |
| Aortic disease | 289 (6.2) | 167 (5.2) | 38 (5.5) | 84 (11.1) | < 0.001 | 14.4 | 0.5 | 3.7 |
| PAD | 434 (9.4) | 294 (9.2) | 75 (10.8) | 65 (8.6) | 0.32 | 5 | 0.46 | 5.7 |
| PTE/DVT | 91 (2.0) | 64 (2.0) | 21 (3.0) | 6 (0.8) | 0.01 | 11.1 | 0.99 | 0.1 |
| Cancer | 1017 (22.0) | 696 (21.9) | 163 (23.5) | 158 (20.9) | 0.48 | 4.2 | 0.29 | 6.8 |
| Chronic lung disease | 597 (12.9) | 380 (11.9) | 119 (17.1) | 98 (13) | 0.001 | 9.9 | 0.26 | 6.2 |
| Infectious disease | 2170 (46.9) | 1286 (40.4) | 521 (75.1) | 363 (48.0) | < 0.001 | 49.4 | 0.45 | 4.9 |
| Beta blocker | 897 (19.4) | 563 (17.7) | 147 (21.2) | 187 (24.7) | < 0.001 | 11.5 | 0.42 | 4.7 |
| RAAS inhibitor | 1281 (27.7) | 891 (28.0) | 180 (25.9) | 210 (27.8) | 0.54 | 3.1 | 0.52 | 5.4 |
| Statin | 1214 (26.2) | 853 (26.8) | 143 (20.6) | 218 (28.8) | 0.001 | 12.8 | 0.82 | 2.3 |
| Antiplatelet | 1469 (31.7) | 975 (30.6) | 222 (32.0) | 272 (36.0) | 0.02 | 7.6 | 0.84 | 1.5 |
| Hemoglobin | 11.9 (± 2.2) | 12.2 (± 2.1) | 10.7 (± 2.1) | 11.6 (± 2.2) | 46.6 | 0.67 | 3.4 | |
| Creatinine | 1.27 (± 1.59) | 1.03 (± 1.19) | 2.05 (± 2.46) | 1.53 (± 1.79) | 36.7 | 0.6 | 2.8 | |
| AST | 41.1 (± 144.5) | 30 (± 56) | 87 (± 291) | 44 (± 187) | 18 | 0.18 | 4.5 | |
| ALT | 35.9 (± 122.4) | 3 (± 50) | 62 (± 200) | 39 (± 209) | 13.1 | 0.14 | 6.2 | |
| ESC/ESA Risk | < 0.001 | 32 | 0.72 | 6.5 | ||||
| High | 733 (15.8) | 460 (14.5) | 74 (10.7) | 199 (26.3) | ||||
| Intermediate | 3409 (73.6) | 2396 (75.3) | 510 (73.5) | 503 (66.5) | ||||
| Low | 490 (10.6) | 326 (10.2) | 110 (15.9) | 54 (7.1) | ||||
| Operative duration, hours | 3.26 (± 2.61) | 3.12 (± 2.25) | 2.94 (± 2.99) | 4.15 (± 3.38) | 26.9 | 0.96 | 0.8 | |
| General anesthesia | 4197 (90.6) | 2892 (90.9) | 620 (89.3) | 685 (90.6) | 0.45 | 3.5 | 0.15 | 8.2 |
| Emergent operation | 1190 (25.7) | 650 (20.4) | 314 (45.2) | 226 (29.9) | < 0.001 | 36.3 | 0.25 | 5.2 |
| Inotropic use | 1315 (28.4) | 637 (20.0) | 281 (40.5) | 397 (52.5) | < 0.001 | 47.3 | 0.63 | 3.3 |
| Colloid use | 2324 (50.2) | 1488 (46.8) | 360 (51.9) | 476 (63.0) | < 0.001 | 21.9 | 0.43 | 4.8 |
| RBC transfusion, pints | 0.78 (± 2.1) | 0.7 (± 0.6) | 0.9 (± 1.0) | 1.0 (± 1.0) | 24.2 | 0.97 | 0.8 | |
Values are n (%) or mean (± SD).
SMD standardized mean difference, BMI body mass index, PAOD peripheral artery disease, PTE/DVT pulmonary thromboembolism/deep vein thrombosis, RAAS renin–angiotensin–aldosterone system, AST aspartate aminotransferase, ALT alanine aminotransferase.
Clinical outcomes.
| n (%) | Univariate analysis | IPW analysis | |||
|---|---|---|---|---|---|
| Unadjusted HR (95% CI) | Adjusted HR (95% CI) | ||||
| Normal | 44 (1.4) | 1 | 1 | ||
| Preoperative myocardial injury | 74 (10.7) | 8.31 (5.72–12.07) | < 0.001 | 3.12 (1.62–6.01) | 0.001 |
| Postoperative myocardial injury | 56 (7.4) | 2.36 (1.94–2.88) | < 0.001 | 4.49 (2.34–8.60) | < 0.001 |
| Pre- vs. postoperative myocardial injury | 0.67 (0.47–0.95) | 0.02 | 1.44 (0.79–2.64) | 0.45 | |
| Normal | 65 (2.0) | 1 | 1 | ||
| Preoperative myocardial injury | 97 (14) | 3.33 (2.42–4.60) | < 0.001 | 2.87 (0.95–3.68) | 0.01 |
| Postoperative myocardial injury | 71 (9.4) | 1.62 (1.37–1.92) | < 0.001 | 2.32 (1.16–4.65) | 0.001 |
| Pre- vs. postoperative myocardial injury | 0.80 (0.59–1.09) | 0.16 | 1.24 (0.68–2.26) | 0.34 | |
| Normal | 201 (6.3) | 1 | 1 | ||
| Preoperative myocardial injury | 71 (10.2) | 2.07 (1.58–2.72) | < 0.001 | 1.30 (0.89–1.89) | 0.18 |
| Postoperative myocardial injury | 71 (9.4) | 1.29 (1.13–1.48) | < 0.001 | 1.61 (1.16–2.23) | 0.004 |
| Pre- vs. postoperative myocardial injury | 0.81 (0.58–1.13) | 0.21 | 1.21 (0.70–2.10) | > 0.99 | |
| Normal | 596 (18.7) | 1 | 1 | ||
| Preoperative myocardial injury | 233 (33.6) | 2.24 (1.92–2.60) | < 0.001 | 1.37 (1.08–1.74) | 0.009 |
| Postoperative myocardial injury | 218 (28.8) | 1.30 (1.20–1.41) | < 0.001 | 1.51 (1.24–1.85) | < 0.001 |
| Pre- vs. postoperative myocardial injury | 0.77 (0.64–0.93) | 0.006 | 1.10 (0.79–1.54) | > 0.99 | |
AKI acute kidney injury.
Figure 2Kaplan–Meier curves for the normal group (grey line), preoperative myocardial injury group (blue line) and postoperative myocardial injury group (red line). Curves for (A) 30-day mortality, (B) mortality during follow-up.
Clinical outcomes of preoperative myocardial injury group.
| Attenuated myocardial injury ( | Persistent myocardial injury ( | Unadjusted HR (95% CI) | ||
|---|---|---|---|---|
| 30-day mortality | 10 (5.6) | 64 (12.4) | 2.23 (1.17–4.44) | 0.02 |
| In-hospital death | 11 (6.2) | 86 (16.6) | 2.10 (1.12–3.94) | 0.02 |
| Overall cardiovascular death | 14 (7.9) | 57 (11.0) | 1.82 (1.01–3.26) | 0.05 |
| Overall all-cause death | 40 (22.6) | 193 (37.3) | 2.03 (1.44–2.86) | < 0.001 |
AKI acute kidney injury.
Figure 3Kaplan–Meier curves for the normal group (black line), attenuated myocardial injury group (grey line), postoperative myocardial injury group (blue line) and persistent myocardial injury group (red line). Curves for (A) 30-day mortality, (B) mortality during follow-up.